 | • レポートコード：MRC2203A083 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界のがんワクチン市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、技術別（組換えがんワクチン、全細胞がんワクチン、ウイルスベクター・DNAがんワクチン、その他技術（樹状細胞、抗原））分析、治療方法別（予防用ワクチン、治療用ワクチン）分析、用途別（前立腺がん、子宮頸がん、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のがんワクチン市場規模：技術別（組換えがんワクチン、全細胞がんワクチン、ウイルスベクター・DNAがんワクチン、その他技術（樹状細胞、抗原）） ・世界のがんワクチン市場規模：治療方法別（予防用ワクチン、治療用ワクチン） ・世界のがんワクチン市場規模：用途別（前立腺がん、子宮頸がん、その他） ・世界のがんワクチン市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Anixa Biosciences Inc.、AstraZeneca PLC、Bristol Myers Squibb Company、…） ・市場機会・将来傾向 |
The cancer vaccines market is projected to register a CAGR of 13.24% during the forecast period, with a revenue of approximately USD 4,825.61 million in 2020 and expected to reach USD 10,175.41 million by 2026.
Due to the sudden outbreak of the COVID-19, the cancer vaccine market observed a significant setback in terms of growth. As the COVID-19 cases were rising, globally the healthcare systems shifted their focus in curbing the disease, thereby, resulting in the delay of prevention, diagnosis, and treatment of other chronic conditions, like cancer. Thus, a negative impact is expected on the cancer vaccine market currently. However, in the forthcoming years, the market is expected to gain momentum due to the relaxation of restrictions and bouncing back of the R&D activities and clinical trials related to cancer vaccines.
Certain factors driving the cancer vaccine market growth include the increasing number of cancer cases, rising investments and government funding in developing cancer vaccines, and technological developments in cancer vaccines.
As per the International Agency for Research on Cancer (IARC), in December 2020, globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men, and 1 in 11 women die from the disease. The IARC estimated that in 2020, the prevalence of cancer rose to 19.3 million cases and 10 million cancer deaths in 2020, which was around 18 million cancer cases around the world in 2018. With this growing burden, the prevention of cancer is one of the most significant challenges. Cancer vaccines play a vital role in the maintenance of the immune system, as they are considered to be biological response modifiers. These cancer vaccines target the infectious agents that may cause cancer through the production of antibodies.
Cancer vaccines are considered a new therapy and are not popular, as compared to the other alternative therapeutic drugs. However, cancer vaccines have shown great potential in both preventive and therapeutic ways. Moreover, as the number of cancer cases is increasing, the development of new cancer vaccines is also increasing for the treatment and prevention of disease. In 2019, Sanofi invested EUR 80 million in BioNTech, a German biotech company, for the development of a messenger RNA cancer vaccine for the treatment of solid tumors.
However, the stringent regulatory issues, along with longer timelines in manufacturing vaccines and the availability of alternative therapies, act as major hindering factors in the global cancer vaccines market’s growth.
Key Market Trends
Recombinant Cancer Vaccines are Expected to a Hold Significant Market Share in the Cancer Vaccines Market
A recombinant vaccine is a vaccine produced through recombinant DNA technology. This includes DNA encoding an antigen, which stimulates an immune response into mammalian cells, expressing the antigen in these cells and then purifying it from them. Many different viruses have been genetically modified to express tumor-associated antigens (TAA) for intramuscular or subcutaneous injection.
Poxviruses have several beneficial features as vectors for cancer vaccines, including broad cell tropism, potent immunogenicity, and pre-existing neutralizing immunity, only in those patients who received the vaccinia virus (the smallpox vaccine). Vaccinia virus, fowlpox virus, and canarypox virus have been investigated clinically for cancer vaccination.
Furthermore, numerous studies are being conducted in the field of viral recombinant cancer vaccines, which may reap positive results in the future, primarily related to cancer vaccination. This is expected to aid the market’s growth. For instance, In July 2019, Oxford Vacmedix UK Limited (OVM), a UK-based biopharma company, collaborated and issued Innovate UK grant to CHAIN Biotechnology Ltd and the University of Oxford to develop OVM-100, a recombinant overlapping peptide (ROP) HPV vaccine targeted at cervical cancer.
However, the recent COVID-19 pandemic has posed a significant negative impact on the respective segment by delaying the development activities of recombinant cancer vaccines.
North America Dominates the Market Over the Forecast Period
North America is expected to grow due to the high prevalence of cancer and developed healthcare infrastructure in the region. The United States has a better healthcare infrastructure than most developed countries. The National Cancer Institute (NCI) stated that the national spending on cancer care is expected to reach USD 156 billion by 2020.
According to the estimates of the GLOBOCAN, in 2020, an estimated 1,95,499 new cases of cancer were diagnosed in Mexico, and 90,222 people died from the disease. The rising number of cancer cases is creating opportunities for market players.
The major market players are focusing on R&D activities to bring new and reliable treatments to the market. In December 2020, Anixa Biosciences, a San Jose, California-based biotech company with Cleveland Clinic, received USFDA investigational new drug application for its new breast cancer vaccine technology developed by Cleveland Clinic immunologist Dr. Vincent Tuohy and his research team to start the first human clinical trials.
Providence Therapeutics is a Toronto-based clinical-stage biotechnology company that develops cancer vaccines for human use. Currently, the company is developing a personalized mRNA cancer vaccine designed to generate strong T cell responses that aim to kill cancer cells and destroy tumors in ovarian cancer, breast cancer, and brain cancer.
Competitive Landscape
The global cancer vaccines market is consolidated and consists of a few major players. Market players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, mergers, and acquisitions. Companies, like AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline, Roche, Merck & Co. Inc., OSE Immunotherapeutics, Sanofi, and Moderna, among others, hold substantial shares in the cancer vaccines market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Cancer
4.2.2 Rising Investments and Government Funding in the Development of Cancer Vaccines
4.2.3 Technological Developments in Cancer Vaccines
4.3 Market Restraints
4.3.1 Stringent Regulatory Guidelines and Longer Timelines Required for Manufacturing Process
4.3.2 Presence of Alternative Therapies
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Recombinant Cancer Vaccines
5.1.2 Whole-cell Cancer Vaccines
5.1.3 Viral Vector and DNA Cancer Vaccines
5.1.4 Other Technologies (Dendritic Cells, Antigen, etc.)
5.2 By Treatment Method
5.2.1 Preventive Vaccine
5.2.2 Therapeutic Vaccine
5.3 By Application
5.3.1 Prostate Cancer
5.3.2 Cervical Cancer
5.3.3 Other Applications
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Anixa Biosciences Inc.
6.1.2 AstraZeneca PLC
6.1.3 Bristol Myers Squibb Company
6.1.4 F Hoffmann-La Roche AG (Genentech)
6.1.5 GlaxoSmithKline PLC
6.1.6 Merck & Co. Inc.
6.1.7 OSE Immunotherapeutics
6.1.8 Sanofi SA
6.1.9 Dendreon Pharmaceuticals LLC
6.1.10 Moderna Inc.
6.1.11 Vaccitech Limited
6.1.12 ProvidenceTherapeutics
6.1.13 eTheRNA immunotherapies
7 MARKET OPPORTUNITIES AND FUTURE TRENDS